share_log

Needham Reiterates Buy on CRISPR Therapeutics, Maintains $90 Price Target

Needham Reiterates Buy on CRISPR Therapeutics, Maintains $90 Price Target

Needham重申买入CRISPR Therapeutics,维持90美元的目标股价
Moomoo 24/7 ·  04/11 06:38

Needham analyst Gil Blum reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and maintains $90 price target.

Needham分析师吉尔·布鲁姆重申CRISPR Therapeutics(纳斯达克股票代码:CRSP)的买入并维持90美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发